An injectable HIV-prevention drug is highly effective - NBC News
WEBSep 12, 2024 · Thrilled over the news Thursday that lenacapavir was 89% more effective at preventing HIV than daily oral preventive medication among gay, bisexual and transgender people, plus previous...
This preventive drug could be a 'game changer' in ending the HIV …
WEB5 days ago · Lenacapavir’s cost as HIV treatment in the United States in 2023 was $42,250 per new patient per year. Oral PrEP options, on the other hand, can cost less than $4 a month. Given the drug’s potential, Tremblay says that it is critical for access to be as widespread as possible. “The infrastructure needs to be in place to reach at-risk ...
Gilead Lenacapavir cut HIV infections by 96% in trial
WEBSep 12, 2024 · A pharmacist holds a vial of lenacapavir, the new HIV prevention injectable drug. Nardus Engelbrecht | AP. Gilead ’s twice-yearly shot reduced HIV infections by 96% in a second large study, the...
Twice-a-year injection reduced risk of HIV infection by 96%, drug …
WEBSep 12, 2024 · In a Phase 3 clinical trial, 99.9% of participants who took a twice-a-year injection of lenacapavir for HIV prevention did not acquire an infection, according to data from drugmaker Gilead...
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced …
WEBSep 12, 2024 · There were 9 incident cases among 1,087 individuals in the Truvada group (incidence 0.93 per 100 person-years). Twice-yearly lenacapavir was 89% more effective than once-daily Truvada (incidence rate ratio 0.11, p=0.00245). In the trial, lenacapavir and Truvada were generally well-tolerated and no significant …
Twice-yearly shot proves successful at preventing HIV infection …
WEBJul 24, 2024 · The twice-yearly injection of the drug lenacapavir can provide total protection against HIV infections, demonstrating 100% efficacy in Phase 3 trial data released by drugmaker Gilead and...
New HIV drug can only offer hope of ending AIDS if all have …
WEBGENEVA, 10 July 2024— UNAIDS has welcomed the release of Gilead Sciences’ trial results on the injectable long-acting HIV medicine Lenacapavir for HIV prevention.
Long-acting injectable lenacapavir proves effective in HIV …
WEBJul 26, 2024 · WHO welcomes the news that long-acting injectable lenacapavir as pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV acquisition in women. This represents a significant breakthrough in HIV prevention. The full results of the PURPOSE 1 trial, presented at the 25th International AIDS Conference, demonstrate the safety and ...
NIH Statement on Preliminary Efficacy Results of Twice-Yearly ...
WEBJun 26, 2024 · The injectable antiretroviral drug lenacapavir was safe and 100% effective as long-acting HIV pre-exposure prophylaxis (PrEP) among cisgender women in a Phase 3 clinical trial, according to top-line findings released by …
Lenacapavir Reduces HIV Infections by 96%, Demonstrates …
WEBSep 12, 2024 · The results demonstrated superiority of twice-yearly lenacapavir over bHIV (incidence 2.37 per 100 person-years), with 96% relative risk reduction (incidence rate ratio 0.04, p<0.0001). 1. There were 9 incident cases among 1,087 individuals in the Truvada group (incidence 0.93 per 100 person-years). Twice-yearly lenacapavir was 89% more ...
Skip to content